143 related articles for article (PubMed ID: 19500983)
21. 4-(1,1-Dioxo-1,4-dihydro-1lambda6-benzo[1,4]thiazin-3-yl)-5-hydroxy-2H-pyridazin-3-ones as potent inhibitors of HCV NS5B polymerase.
Ellis DA; Blazel JK; Webber SE; Tran CV; Dragovich PS; Sun Z; Ruebsam F; McGuire HM; Xiang AX; Zhao J; Li LS; Zhou Y; Han Q; Kissinger CR; Showalter RE; Lardy M; Shah AM; Tsan M; Patel R; LeBrun LA; Kamran R; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L
Bioorg Med Chem Lett; 2008 Aug; 18(16):4628-32. PubMed ID: 18662878
[TBL] [Abstract][Full Text] [Related]
22. Design and synthesis of indole, 2,3-dihydro-indole, and 3,4-dihydro-2H-quinoline-1-carbothioic acid amide derivatives as novel HCV inhibitors.
Kang IJ; Wang LW; Hsu SJ; Lee CC; Lee YC; Wu YS; Hsu TA; Yueh A; Chao YS; Chern JH
Bioorg Med Chem Lett; 2009 Aug; 19(15):4134-8. PubMed ID: 19539472
[TBL] [Abstract][Full Text] [Related]
23. Effects of the aryl linker and the aromatic substituent on the anti-HCV activities of aryl diketoacid (ADK) analogues.
Kim J; Kim KS; Lee HS; Park KS; Park SY; Kang SY; Lee SJ; Park HS; Kim DE; Chong Y
Bioorg Med Chem Lett; 2008 Aug; 18(16):4661-5. PubMed ID: 18644717
[TBL] [Abstract][Full Text] [Related]
24. Studies on acyl pyrrolidine inhibitors of HCV RNA-dependent RNA polymerase to identify a molecule with replicon antiviral activity.
Burton G; Ku TW; Carr TJ; Kiesow T; Sarisky RT; Lin-Goerke J; Hofmann GA; Slater MJ; Haigh D; Dhanak D; Johnson VK; Parry NR; Thommes P
Bioorg Med Chem Lett; 2007 Apr; 17(7):1930-3. PubMed ID: 17270443
[TBL] [Abstract][Full Text] [Related]
25. Des-A-ring benzothiadiazines: inhibitors of HCV genotype 1 NS5B RNA-dependent RNA polymerase.
Donner PL; Xie Q; Pratt JK; Maring CJ; Kati W; Jiang W; Liu Y; Koev G; Masse S; Montgomery D; Molla A; Kempf DJ
Bioorg Med Chem Lett; 2008 Apr; 18(8):2735-8. PubMed ID: 18362072
[TBL] [Abstract][Full Text] [Related]
26. Design, synthesis, and structure-activity relationships of novel imidazo[4,5-c]pyridine derivatives as potent non-nucleoside inhibitors of hepatitis C virus NS5B.
Liu M; Xu Q; Guo S; Zuo R; Hong Y; Luo Y; Li Y; Gong P; Liu Y
Bioorg Med Chem; 2018 May; 26(9):2621-2631. PubMed ID: 29681484
[TBL] [Abstract][Full Text] [Related]
27. Parallel synthesis of 5-cyano-6-aryl-2-thiouracil derivatives as inhibitors for hepatitis C viral NS5B RNA-dependent RNA polymerase.
Ding Y; Girardet JL; Smith KL; Larson G; Prigaro B; Wu JZ; Yao N
Bioorg Chem; 2006 Feb; 34(1):26-38. PubMed ID: 16360193
[TBL] [Abstract][Full Text] [Related]
28. Recent advances on the synthesis of hepatitis C virus NS5B RNA-dependent RNA-polymerase inhibitors.
Zhao C; Wang Y; Ma S
Eur J Med Chem; 2015 Sep; 102():188-214. PubMed ID: 26276434
[TBL] [Abstract][Full Text] [Related]
29. Inhibitors of HCV NS5B polymerase: synthesis and structure-activity relationships of N-1-benzyl and N-1-[3-methylbutyl]-4-hydroxy-1,8-naphthyridon-3-yl benzothiadiazine analogs containing substituents on the aromatic ring.
Rockway TW; Zhang R; Liu D; Betebenner DA; McDaniel KF; Pratt JK; Beno D; Montgomery D; Jiang WW; Masse S; Kati WM; Middleton T; Molla A; Maring CJ; Kempf DJ
Bioorg Med Chem Lett; 2006 Jul; 16(14):3833-8. PubMed ID: 16650984
[TBL] [Abstract][Full Text] [Related]
30. Structure-based design, synthesis, and biological evaluation of 1,1-dioxoisothiazole and benzo[b]thiophene-1,1-dioxide derivatives as novel inhibitors of hepatitis C virus NS5B polymerase.
Kim SH; Tran MT; Ruebsam F; Xiang AX; Ayida B; McGuire H; Ellis D; Blazel J; Tran CV; Murphy DE; Webber SE; Zhou Y; Shah AM; Tsan M; Showalter RE; Patel R; Gobbi A; LeBrun LA; Bartkowski DM; Nolan TG; Norris DA; Sergeeva MV; Kirkovsky L; Zhao Q; Han Q; Kissinger CR
Bioorg Med Chem Lett; 2008 Jul; 18(14):4181-5. PubMed ID: 18554907
[TBL] [Abstract][Full Text] [Related]
31. Computer-aided identification, synthesis and evaluation of substituted thienopyrimidines as novel inhibitors of HCV replication.
Bassetto M; Leyssen P; Neyts J; Yerukhimovich MM; Frick DN; Brancale A
Eur J Med Chem; 2016 Nov; 123():31-47. PubMed ID: 27474921
[TBL] [Abstract][Full Text] [Related]
32. Synthesis of pyrrolo[2,3-d]pyrimidine nucleoside derivatives as potential anti-HCV agents.
Varaprasad CV; Ramasamy KS; Girardet JL; Gunic E; Lai V; Zhong W; An H; Hong Z
Bioorg Chem; 2007 Feb; 35(1):25-34. PubMed ID: 16945403
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of the anti-hepatitis C virus effect of novel potent, selective, and orally bioavailable JNK and VEGFR kinase inhibitors.
Raboisson P; Lenz O; Lin TI; Surleraux D; Chakravarty S; Scholliers A; Vermeiren K; Delouvroy F; Verbinnen T; Simmen K
Bioorg Med Chem Lett; 2007 Apr; 17(7):1843-9. PubMed ID: 17289388
[TBL] [Abstract][Full Text] [Related]
34. Active site inhibitors of HCV NS5B polymerase. The development and pharmacophore of 2-thienyl-5,6-dihydroxypyrimidine-4-carboxylic acid.
Stansfield I; Avolio S; Colarusso S; Gennari N; Narjes F; Pacini B; Ponzi S; Harper S
Bioorg Med Chem Lett; 2004 Oct; 14(20):5085-8. PubMed ID: 15380204
[TBL] [Abstract][Full Text] [Related]
35. Novel 4-thiazolidinones as non-nucleoside inhibitors of hepatitis C virus NS5B RNA-dependent RNA polymerase.
Çakir G; Küçükgüzel İ; Guhamazumder R; Tatar E; Manvar D; Basu A; Patel BA; Zia J; Talele TT; Kaushik-Basu N
Arch Pharm (Weinheim); 2015 Jan; 348(1):10-22. PubMed ID: 25449674
[TBL] [Abstract][Full Text] [Related]
36. Preparation and biological evaluation of 1'-cyano-2'-C-methyl pyrimidine nucleosides as HCV NS5B polymerase inhibitors.
Mish MR; Cho A; Kirschberg T; Xu J; Zonte CS; Fenaux M; Park Y; Babusis D; Feng JY; Ray AS; Kim CU
Bioorg Med Chem Lett; 2014 Jul; 24(14):3092-5. PubMed ID: 24907145
[TBL] [Abstract][Full Text] [Related]
37. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 3: Further optimization of the 2-, 6-, and 7'-substituents and initial pharmacokinetic assessments.
Li LS; Zhou Y; Murphy DE; Stankovic N; Zhao J; Dragovich PS; Bertolini T; Sun Z; Ayida B; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Showalter RE; Patel R; Lebrun LA; Bartkowski DM; Nolan TG; Norris DA; Kamran R; Brooks J; Sergeeva MV; Kirkovsky L; Zhao Q; Kissinger CR
Bioorg Med Chem Lett; 2008 Jun; 18(11):3446-55. PubMed ID: 18457949
[TBL] [Abstract][Full Text] [Related]
38. Allosteric inhibitors of hepatitis C virus NS5B polymerase thumb domain site II: structure-based design and synthesis of new templates.
Malancona S; Donghi M; Ferrara M; Martin Hernando JI; Pompei M; Pesci S; Ontoria JM; Koch U; Rowley M; Summa V
Bioorg Med Chem; 2010 Apr; 18(8):2836-48. PubMed ID: 20363140
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and anti-HCV activity evaluation of anilinoquinoline derivatives.
Peng HK; Lin CK; Yang SY; Tseng CK; Tzeng CC; Lee JC; Yang SC
Bioorg Med Chem Lett; 2012 Jan; 22(2):1107-10. PubMed ID: 22204909
[TBL] [Abstract][Full Text] [Related]
40. Novel HCV NS5B polymerase inhibitors derived from 4-(1',1'-dioxo-1',4'-dihydro-1'lambda(6)-benzo[1',2',4']thiadiazin-3'-yl)-5-hydroxy-2H-pyridazin-3-ones. Part 2: Variation of the 2- and 6-pyridazinone substituents.
Zhou Y; Li LS; Dragovich PS; Murphy DE; Tran CV; Ruebsam F; Webber SE; Shah AM; Tsan M; Averill A; Showalter RE; Patel R; Han Q; Zhao Q; Hermann T; Kissinger CR; Lebrun L; Sergeeva MV
Bioorg Med Chem Lett; 2008 Feb; 18(4):1419-24. PubMed ID: 18226901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
